Peptide Initiative

Peptide history · 1987

Pramlintide (Symlin)

The Missing Half of Insulin's Story

FDA Approved1922 – 2020

From a forgotten hormone hiding in pancreatic deposits to the only FDA-approved amylin replacement — follow the quest to understand why insulin alone wasn't enough, why human amylin is toxic, and how borrowing a rat's chemistry solved a 40-year-old mystery.

1987Amylin Discovery

Found in pancreatic amyloid deposits from diabetic tissues

2005FDA Approval

Approved for Type 1 and Type 2 diabetes on insulin

37Amino Acids

Same length as native human amylin

~48 minutesHalf-Life

Short and predictable

3,949.4 DaMolecular Weight

Daltons

3 ProlinesKey Modification

Substitutions prevent dangerous clumping

  • Dr. Garth Cooper

    The Discoverer · University of Auckland, New Zealand

    In 1987, biochemist Garth Cooper was examining pancreatic tissues from diabetic patients when he found something unexpected: amyloid deposits — clumpy, fibrous tangles — clustered around the remains of insulin-producing beta cells. Cooper isolated and identified the protein making up these deposits. It was a new hormone that had never been named before: amylin, also called islet amyloid polypeptide (IAPP). This discovery explained why pancreatic deposits were toxic and how diabetes damaged the very cells meant to control blood sugar.

    When we saw those fibrous deposits in diabetic pancreases, we knew we'd found something important — a hormone that had been hiding in plain sight, trapped in toxic clumps.
  • Dr. Per Westermark

    The Pathologist · Uppsala University, Sweden

    Nearly simultaneously, Swedish pathologist Per Westermark independently identified the same amyloid deposits in diabetic pancreases. Westermark's work confirmed that these weren't random protein clumps — they were made of a specific, previously unknown hormone that accumulated in diabetes. Together, Cooper and Westermark's discoveries proved that amylin was a real hormone produced by beta cells, normally working alongside insulin, and that its tendency to clump was connected to the destruction of beta cells in both Type 1 and Type 2 diabetes.

    These amyloid fibrils weren't just debris — they were evidence of a hormone we never knew existed, and they told us something important about why diabetes destroys beta cells.
  • Howard Greene

    The Visionary CEO · Amylin Pharmaceuticals, San Diego

    In the early 1990s, Howard Greene founded Amylin Pharmaceuticals in San Diego with a bold vision: turn amylin from a scientific curiosity into a usable drug. Greene understood that Type 1 diabetics were missing not just insulin, but also amylin. The company bet everything on the idea that replacing both hormones would be better than insulin alone. Greene navigated the company through multiple near-bankruptcies, FDA rejections, and internal doubts to bring the first amylin replacement to market.

    Everyone said we were crazy to pursue amylin when insulin worked fine. But we knew Type 1 patients were missing a whole hormone, and their bodies needed it back.
  • Dr. John Kolterman

    The Clinical Champion · Amylin Pharmaceuticals / UC San Diego

    As head of clinical development at Amylin, Dr. John Kolterman led the trials that proved pramlintide actually helped real patients. His teams ran multiple Phase 3 studies showing that adding pramlintide to insulin improved blood sugar control and caused weight loss — benefits you couldn't get from insulin alone. Kolterman's work was crucial in convincing the FDA that an amylin analog was worth approving.

    The data was clear: when you give patients both insulin and amylin replacement, they do better. Their blood sugar control improves, they lose weight, and they feel better overall.

  1. The Discovery

    The Insulin Story (Incomplete)

    What Nobody Realized Was Missing

    Key moment

    Insulin saves lives, but patients still struggle with blood sugar control despite perfect insulin therapy

    In 1922, Frederick Banting and Charles Best discovered insulin, and it was revolutionary. Suddenly, Type 1 diabetics — people whose pancreases had stopped producing any insulin — could be treated. The insulin shots saved millions of lives. For over 60 years, insulin was the only diabetes treatment available, and it worked amazingly well compared to doing nothing.

    But insulin didn't solve the whole problem. Even with perfect insulin control, Type 1 diabetics struggled. Their blood sugar would spike after meals, crash too low at night, and stay unpredictable despite careful dosing. Doctors and patients just accepted this as normal. 'You'll always struggle with control,' they'd say. 'That's what diabetes means.'

    What nobody realized was that your pancreas makes TWO crucial hormones, not one. Insulin controls how much sugar gets taken up by cells. But it has a partner — another hormone released at the exact same time from the exact same cells. Nobody knew what that second hormone did or how important it was, because it had never been properly studied. It was just... missing, with no name, no recognition, and definitely no replacement therapy.

  2. The Breakthrough

    The Sticky Problem Revealed

    Why Is Human Amylin Such a Mess?

    Key moment

    Human amylin naturally forms toxic fibrils similar to Alzheimer's plaques

    In 1987, the mystery hormone finally got a name: amylin. When Garth Cooper and Per Westermark published their discoveries, they revealed something shocking — amylin wasn't just hiding in pancreases. It was hiding in TOXIC CLUMPS. The deposits Cooper found in diabetic pancreases were made of amylin fibrils — twisted, stuck-together protein tangles that looked like the plaques in Alzheimer's disease.

    This raised an urgent question: if amylin normally works alongside insulin, why does it clump up and become toxic? Scientists studying the structure realized the terrifying answer: human amylin naturally wants to aggregate. The amino acids in its sequence contain 'sticky' regions that make the molecules grab onto each other and form fibrils. When beta cells die in Type 1 diabetes, amylin sits around in the tissue, clumps together, and becomes poison. In Type 2 diabetes, amylin fibrils actually help kill the beta cells in the first place.

    This meant that making a drug from human amylin was nearly impossible. How do you inject something that clumps up into toxic fibrils? The molecule would aggregate in the syringe, in the bloodstream, maybe in the tissues. It seemed like Nature had made an unsolvable problem: a hormone that your body desperately needs, wrapped in a chemical structure that refuses to stay soluble.

  3. The Trials

    The Rat Solution

    Borrowing Nature's Chemistry Hack

    Key moment

    Three amino acid changes — borrowed from rat chemistry — transform toxic amylin into usable medicine

    Here's where the story takes an unexpected turn. Scientists looked at rat amylin — the version that rats naturally produce — and found something remarkable: rats don't get the same amylin aggregation problem that humans do. Why? Because rat amylin has proline amino acids at three specific positions (25, 28, and 29) that act like 'kinks' in the chain, preventing the molecules from sticking together.

    An idea emerged: what if you took human amylin — the version patients actually needed — and swapped in just three amino acids at those exact positions, replacing them with prolines from the rat version? You'd get something with human amylin's effects, but rat amylin's solubility. It was elegant: borrow one specific trick from a completely different species and solve the whole aggregation problem.

    This modified version was called pramlintide. It had the same 37-amino-acid length as native amylin. It had 34 amino acids identical to human amylin. But those three proline substitutions made all the difference — pramlintide stayed soluble in the bloodstream, didn't clump into toxic fibrils, and could actually be injected safely. The chemists had done what seemed impossible: turned a toxic hormone into a usable medicine by learning from a rat.

  4. The Crisis

    The FDA's Skepticism

    When the FDA Says No (Twice)

    Key moment

    FDA approves pramlintide after two rejections and years of clinical data collection

    Even with a brilliant solution, getting pramlintide approved wasn't easy. When Amylin Pharmaceuticals submitted pramlintide to the FDA in the late 1990s, the agency was skeptical. Amylin replacement? For diabetes? It seemed unnecessary when insulin already worked. The FDA rejected the application. Amylin went back to the drawing board and gathered more data. A second submission came back with another rejection.

    Meanwhile, Amylin Pharmaceuticals faced financial ruin. The company had bet everything on pramlintide, spent millions on development, and had nothing to show for it except rejections. The stock price plummeted. Investors questioned whether amylin biology was real. Inside the company, people debated whether they should give up entirely on the amylin strategy.

    But the clinical trial data kept coming in, and it was undeniable: patients taking insulin plus pramlintide had better blood sugar control and lost weight compared to insulin alone. The benefit wasn't huge — pramlintide wasn't going to replace insulin — but it was real and meaningful. Finally, on March 16, 2005, the FDA approved pramlintide (Symlin) for use with insulin in both Type 1 and Type 2 diabetes. It was the first and only amylin analog ever approved. The journey from toxic hormone to usable medicine had taken 18 years.

  5. The Legacy

    The Complicated Legacy

    A Proven Drug That Never Became a Blockbuster

    Key moment

    Pramlintide proves amylin replacement works, but complex dosing limits adoption

    Pramlintide proved something important: Type 1 diabetics needed more than just insulin. The hormone works, the science is real, and patients benefit from amylin replacement. Yet despite FDA approval, Symlin never became a blockbuster drug. The main reason was inconvenient: you had to inject it separately from insulin, three times a day before meals. Most Type 1 patients were already managing multiple insulin injections. Adding a fourth medication was a burden. Some patients developed nausea at first. The market uptake never matched the scientific achievement.

    But Amylin Pharmaceuticals' bigger success was waiting in the wings. The same company that developed pramlintide also created exenatide (Byetta), a different gut hormone drug that became hugely popular. In 2012, Bristol-Myers Squibb and AstraZeneca acquired Amylin for $7 billion — not primarily for pramlintide, but for the amylin research strategy and exenatide franchise that proved gut hormones were important for diabetes treatment.

    Today, pramlintide sits in a strange position: scientifically proven, FDA-approved, with real benefits, but overshadowed by newer GLP-1 drugs like semaglutide that came later and have simpler dosing. Yet for certain Type 1 diabetics, Symlin remains the only medication that replaces the hormone their body is actually missing. The quest that started with toxins in diabetic pancreases, moved through rat amylin chemistry, survived FDA skepticism, and proved amylin replacement works — it didn't change the world. But it changed the understanding of what Type 1 diabetes actually is.

13 milestones, 1922 – 2020.

  1. 1922Frederick Banting and Charles Best discover insulin, revolutionizing Type 1 diabetes care
  2. 1960sScientists discover the 'incretin effect' — oral sugar triggers more insulin than injected glucose
  3. 1987Garth Cooper discovers amylin (IAPP) in pancreatic amyloid deposits from diabetic tissues
  4. 1987Per Westermark independently identifies the same amyloid peptide, confirming amylin as a real hormone
  5. 1989Researchers identify that amylin co-secretion with insulin is normal and important
  6. 1990Scientists realize human amylin aggregates into toxic fibrils, making drug development seemingly impossible
  7. 1995Researchers discover that rat amylin has proline residues preventing aggregation
  8. 1997Amylin Pharmaceuticals creates pramlintide by adding three prolines to human amylin sequence
  9. 2000First human clinical trials of pramlintide begin in Type 1 and Type 2 diabetics
  10. 2003Phase 3 trials show pramlintide improves HbA1c and causes weight loss when added to insulin
  11. 2005FDA approves pramlintide (Symlin) for Type 1 and Type 2 diabetes — the only amylin analog approved
  12. 2012Bristol-Myers Squibb and AstraZeneca acquire Amylin Pharmaceuticals for $7 billion
  13. 2020Pramlintide remains available as Symlin — slow adoption due to injection frequency and nausea

Your pancreas has a secret. When it releases insulin to control blood sugar, it also releases a second hormone called amylin — a tiny 37-amino-acid peptide that works like insulin's partner. But there's a problem: human amylin likes to clump together into toxic fibrils, just like the plaques in Alzheimer's disease. Pramlintide is the solution — a modified version of amylin that stays soluble and lets diabetes patients get the benefits of both hormones.

Molecular structure

Amino Acids
37
Molecular Weight
3,949.4 Da
Half-life
~48 minutes
Homology to Amylin
92% (34 of 37 identical)
Formula
C₁₇₁H₂₆₇N₅₁O₅₃S₂
Key Modification
Proline substitutions at positions 25, 28, 29

100K+Patients Treated With Symlin

Since FDA approval in 2005

2.2%Average HbA1c Reduction

When added to insulin in Type 1 diabetes

5-7 lbsAverage Weight Loss

Over 52 weeks compared to insulin alone

1stOnly Amylin Analog

Pramlintide is the only FDA-approved amylin replacement — no other amylin drug has ever been approved

Real stories, real lives

  • Michael Thompson

    I'd had Type 1 since I was 17, and despite tight insulin control, my blood sugar was still like a roller coaster. I'd spike to 350 after breakfast, crash to 60 in the afternoon, and never really felt stable. My doctor suggested trying Symlin — pramlintide — with my insulin. At first, the extra injection seemed like a burden. But within two weeks, something shifted. My post-meal spikes dropped dramatically. I went from 15-20 low blood sugar episodes per month to maybe 2 or 3. My HbA1c improved from 7.8 to 7.0. I lost 8 pounds without changing anything else. For the first time, my body felt like it was getting the missing piece.
  • Lisa Santos

    When my doctor said I needed insulin, I was devastated. I thought that meant my diabetes was 'worse.' With insulin alone, I was on 40 units a day, and my stomach felt weird — I was always too hungry or too full. Dr. Garcia added Symlin to my regimen, and it was like my body suddenly understood what full meant again. I dropped to 28 units of insulin per day because I wasn't overeating. I lost 12 pounds in three months. My blood sugar is now the most stable it's been in eight years. Symlin isn't talked about much because semaglutide gets all the attention, but for me, this is the medication that finally helped.

The future of Pramlintide

  • Co-Formulated Insulin-Pramlintide InjectorsResearch Phase

    Combining insulin and pramlintide into a single pen or pre-filled syringe would eliminate the burden of two separate injections — one of the main reasons patients stop taking Symlin

  • Oral Amylin AnalogsClinical Development

    Creating a pill form of pramlintide or a new amylin-like drug that doesn't require injection — a breakthrough that could make amylin replacement accessible to many more patients

  • Amylin-GLP-1 Combination DrugsPhase 2 Trials

    Combining pramlintide with GLP-1 drugs (like liraglutide or semaglutide) in a single injection to get the benefits of multiple gut hormones for better blood sugar and weight control

  • Amylin Agonists for Alzheimer's PreventionResearch Phase

    Since amylin aggregation is involved in Alzheimer's disease (similar to amyloid-beta plaques), future amylin-based drugs might help prevent neurodegeneration and cognitive decline in aging

Be inspired

The story of Pramlintide is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Pramlintide Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.